[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Beyond Air Inc (XAIR)

Beyond Air Inc (XAIR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,326
  • Shares Outstanding, K 14,411
  • Annual Sales, $ 7,680 K
  • Annual Income, $ -33,250 K
  • EBIT $ -29 M
  • EBITDA $ -25 M
  • 60-Month Beta 0.22
  • Price/Sales 0.88
  • Price/Cash Flow N/A
  • Price/Book 0.99
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -4.40
  • Most Recent Earnings $-0.77 on 06/26/26
  • Next Earnings Date 08/11/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $-3.00
  • Growth Rate Est. (year over year) +33,400.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3345 +29.93%
on 06/16/26
0.5250 -17.22%
on 06/26/26
+0.0218 (+5.28%)
since 06/05/26
3-Month
0.3345 +29.93%
on 06/16/26
0.8209 -47.06%
on 04/10/26
-0.2754 (-38.79%)
since 04/07/26
52-Week
0.3345 +29.93%
on 06/16/26
4.7800 -90.91%
on 09/08/25
-3.3614 (-88.55%)
since 07/07/25

Most Recent Stories

More News
Beyond Air® Reports Fourth Quarter and Full Year 2026 Financial Results and Provides Corporate Update

Revenue increased by 107% year-over-year to $7.7 million in the full fiscal year 2026; increased revenue by 66% YoY in the fiscal fourth quarter 2026 The Company is transitioning its year-end from...

XAIR : 0.4300 (-2.05%)
Beyond Air Schedules Fiscal Year End 2026 Financial Results Conference Call and Webcast

GARDEN CITY, N.Y., June 22, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on...

XAIR : 0.4300 (-2.05%)
Beyond Air, Inc. Urges Stockholders to Vote “FOR” All Proposals Ahead of the Upcoming Special Meeting

Special Meeting of Stockholders Scheduled for June 18, 2026 at 4:30 p.m. Eastern Time Proxies have been mailed to stockholders of record as of the close of business on April 20, 2026; contact information...

XAIR : 0.4300 (-2.05%)
Beyond Air Receives Nasdaq Hearing Panel Decision Granting Continued Listing

GARDEN CITY, N.Y., June 01, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO)...

XAIR : 0.4300 (-2.05%)
Beyond Cancer Reports Updated Survival and Safety Data from Phase 1 UNO Trial Presented at AACR 2026

Updated AACR poster data show continued survival follow-up in heavily pre ‑ treated patients following a single intratumoral UNO injection Received US patent allowance covering proprietary gas...

XAIR : 0.4300 (-2.05%)
Beyond Air to Participate in the D. Boral Capital Global Conference 2026

GARDEN CITY, N.Y., April 15, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide...

XAIR : 0.4300 (-2.05%)
Beyond Air Expands Commercial Access for LungFit® PH Through a Purchasing Agreement with a Top 3 National Group Purchasing Organization (GPO)

GARDEN CITY, N.Y., April 01, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide...

XAIR : 0.4300 (-2.05%)
Beyond Air, Inc. Announces Resignation of Steve Lisi, CEO, and Appointment of Robert Goodman, Chief Commercial Officer, as CEO

GARDEN CITY, N.Y., March 26, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused...

XAIR : 0.4300 (-2.05%)
Beyond Cancer Reports Early Clinical Activity and Favorable Safety Profile with Interim Data from Phase 1 UNO Trial

GARDEN CITY, N.Y., March 17, 2026 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., a clinical stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an investigational immunotherapeutic...

XAIR : 0.4300 (-2.05%)
Beyond Air to Participate in the 38th Annual Roth Conference in March

GARDEN CITY, N.Y., March 11, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing...

XAIR : 0.4300 (-2.05%)

Business Summary

Beyond Air Inc. is a clinical-stage medical device and biopharmaceutical company. It is engaged in developing a Nitric Oxide Generator and Delivery System. The company's principal product is AirNOvent which is in clinical stage. Beyond Air Inc., formerly known as AIT Therapeutics Inc., is based in Garden...

See More

Key Turning Points

3rd Resistance Point 0.5072
2nd Resistance Point 0.4882
1st Resistance Point 0.4636
Last Price 0.4300
1st Support Level 0.4200
2nd Support Level 0.4010
3rd Support Level 0.3764

See More

52-Week High 4.7800
Fibonacci 61.8% 3.0818
Fibonacci 50% 2.5573
Fibonacci 38.2% 2.0327
Last Price 0.4300
52-Week Low 0.3345

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.